Company / Shareholders' Equity
Bausch & Lomb Corp Shareholders' Equity History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$6.4B
FY2025
5-year range
$6.4B / $9.4B
FY2021-FY2025
Trend
-0.4%
vs FY2024
Sector context
#29 of 166
Health Care
What the data says
Bausch & Lomb Corp's shareholders' equity of $6.4B is higher than 83% of companies in the Health Care sector (FY2025). Shareholders' Equity has declined for 5 consecutive years, from $10.0B in FY2020 to $6.4B in FY2025.
Based on SEC 10-K filings.
$6.4B in FY2025 with a 5-year CAGR of -8.4%. Top quartile in the Health Care sector.
Declined from $6.8B to $6.4B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -2.9%
- 5-Year CAGR
- -8.4%
- 10-Year CAGR
- -
Sector benchmark
+22.7% above sector average
Key checks
Key Insights
- Bausch & Lomb Corp's shareholders' equity has declined for 5 consecutive years.
- 5-year CAGR of -8.4%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 0.4% year-over-year.
- Ranks #29 out of 166 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.74 (distress zone, below 1.8 threshold)
- Negative profit margin: -6.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.4B | -0.4% |
| FY2024 | $6.5B | -5.5% |
| FY2023 | $6.8B | -2.6% |
| FY2022 | $7.0B | -25.2% |
| FY2021 | $9.4B | -5.9% |
| FY2020 | $10.0B | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026